Soleno Therapeutics Inc represents a commitment to improving the lives of patients by developing innovative therapies. The company focuses on addressing unmet medical needs in rare diseases, with a particular emphasis on neurodevelopmental and metabolic disorders. Soleno Therapeutics Inc strives for excellence in research and development, aiming to bring groundbreaking treatments to market. With a patient-centered approach, the company aims to provide hope and improve outcomes for individuals and families affected by these conditions. Soleno Therapeutics Inc envisions a future where better treatments are accessible to all, advocating for improved healthcare and quality of life.

Soleno Therapeutics Inc is primarily present in the United States.

Soleno Therapeutics Inc has achieved several significant milestones in its journey. The company successfully developed a novel therapeutic candidate, Diazoxide Choline Controlled-Release (DCCR), to treat Prader-Willi Syndrome (PWS). In clinical studies, DCCR demonstrated promising results by addressing hyperphagia, a critical symptom of PWS. Soleno Therapeutics Inc also received Orphan Drug Designation for DCCR from the FDA, recognizing the potential to treat a rare and serious condition. The company continues to advance DCCR's development and explore its potential in other indications. Soleno Therapeutics Inc's commitment to innovation and dedication towards addressing unmet medical needs underscores its remarkable achievements in the field.

Soleno Therapeutics Inc is a biopharmaceutical company based in California, United States. It was founded in 1999 under the name Capnia, Inc and changed its name to Soleno Therapeutics in 2017. The company specializes in developing innovative therapeutic solutions for rare diseases. Soleno Therapeutics focuses on areas such as neurology, endocrinology, and rare genetic diseases. They aim to transform patients' lives by delivering effective treatments. With a dedicated team of researchers and scientists, Soleno Therapeutics is committed to providing novel therapies to address unmet medical needs. Soleno Therapeutics Inc has made significant strides in the field of rare diseases and continues to contribute to advancements in healthcare.

Soleno Therapeutics Inc faces competition from several companies in the market. Some of its main competitors include companies such as Neurocrine Biosciences, Novo Nordisk, and Ascendis Pharma. These companies are also involved in the development and commercialization of innovative therapies and treatments for various medical conditions. However, Soleno Therapeutics Inc differentiates itself through its unique product offerings and focus on specific areas of medical need. It strives to provide effective solutions and improve patient outcomes, making it a formidable player in the competitive landscape.

Soleno Therapeutics Inc is primarily active in the pharmaceutical industry.

The business model of Soleno Therapeutics Inc revolves around developing and commercializing innovative therapeutic products for rare diseases. As a biopharmaceutical company, Soleno focuses on identifying, acquiring, and advancing promising technologies to address unmet medical needs. By leveraging its expertise in drug development and medical research, Soleno aims to bring novel and effective treatments to patients suffering from rare diseases. Through strategic collaborations, clinical trials, and regulatory approvals, Soleno Therapeutics Inc strives to improve the quality of life for individuals affected by these conditions.

Hệ số P/E của Soleno Therapeutics là -9,60.

Chỉ số P/S của Soleno Therapeutics là 0.

Chỉ số chất lượng AlleAktien của Soleno Therapeutics là 2/10.

Doanh thu hiện không thể tính toán được cho Soleno Therapeutics.

Lợi nhuận kỳ vọng Soleno Therapeutics là -96,00 tr.đ. USD.

Soleno Therapeutics Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare diseases. The company was founded in 1999 and is headquartered in Redwood City, California. Soleno Therapeutics focuses on developing therapies for rare diseases that have often been neglected by the pharmaceutical industry. The company currently offers two products: DiaPep277, an immunotherapy for the treatment of type 1 diabetes, and Caz-Avi, an antimicrobial therapy for the treatment of gram-negative bacterial infections. To successfully market these products, Soleno Therapeutics has two main business areas: research and development, and sales and marketing. The research and development department is responsible for identifying, developing, and testing new therapy approaches. The company has an experienced team of scientists and developers who pursue innovative approaches in therapy development. Soleno Therapeutics's sales and marketing department is responsible for effectively marketing the products and building a network of doctors and hospitals to increase sales. The company has a dedicated team of sales and marketing experts who work closely with medical professionals to ensure that the products provide the best possible patient care. Soleno Therapeutics has also established strong partnerships with other pharmaceutical companies and research institutions to accelerate the development of therapies for rare diseases. The company collaborates with these partners to carry out joint research and development projects and exchange ideas to speed up therapy development. Soleno Therapeutics is a successful biopharmaceutical company specializing in the development of therapies for rare diseases. The company has a strong pipeline of innovative products and works closely with its partners to accelerate therapy development. Soleno Therapeutics remains committed to expanding comprehensive treatment for patients with rare diseases.

Soleno Therapeutics cổ tức hàng năm là 0 USD, được phân phối qua lần thanh toán trong năm.

Hiện tại không thể tính toán được cổ tức cho Soleno Therapeutics hoặc công ty không chi trả cổ tức.

Mã ISIN của Soleno Therapeutics là US8342032005.

Mã WKN của Soleno Therapeutics là A2JSTG.

Mã chứng khoán của Soleno Therapeutics là SLNO.

Trong vòng 12 tháng qua, Soleno Therapeutics đã trả cổ tức là . Điều này tương đương với lợi suất cổ tức khoảng . Dự kiến trong 12 tháng tới, Soleno Therapeutics sẽ trả cổ tức là 0 USD.

Lợi suất cổ tức của Soleno Therapeutics hiện nay là .

Soleno Therapeutics trả cổ tức hàng quý. Số tiền này được phân phối vào các tháng .

Soleno Therapeutics đã thanh toán cổ tức hàng năm trong 0 năm qua.

Trong 12 tháng tới, người ta kỳ vọng cổ tức sẽ đạt 0 USD. Điều này tương đương với tỷ suất cổ tức là 0 %.

Soleno Therapeutics được phân loại vào ngành 'Sức khỏe'.

Để nhận được cổ tức cuối cùng của Soleno Therapeutics vào ngày 3/11/2024 với số tiền 0 USD, bạn phải có cổ phiếu trong tài khoản trước ngày không hưởng quyền vào 3/11/2024.

Việc thanh toán cổ tức cuối cùng đã được thực hiện vào 3/11/2024.

Vào năm 2023, Soleno Therapeutics đã phân phối 0 USD dưới hình thức cổ tức.

Cổ tức của Soleno Therapeutics được phân phối bằng USD.